NCT06567418 - Retrospective Analysis of the Effect of In-hospital Initiation of PCSK9i on Clinical Outcomes in Chinese ACS Patients | Biotech Hunter

Enrollment

10,000

Participants

Timeline

Start Date

August 1, 2024

Primary Completion Date

August 31, 2024

Study Completion Date

January 31, 2025

Conditions

Acute Coronary Syndrome

Interventions

DRUG

alirocumab 75mg/2week

patients continually prescribed or stopped alirocumab treatment during the follow-up visit, which depend on physician's clinical decision and patient preference

DRUG

statin ± ezetimibe

patients will be censored at initiation of alirocumab during the follow up visit

Trial Locations (1)

100853

RECRUITING

Chinese PLA General Hospital, Beijing